Effect of DNMT3A R882H Hot Spot Mutations on DDX43 Promoter Methylation in Acute Myeloid Leukemia

Table 1

Clinical and laboratory characteristics of AML patients and controls.

Laboratory characteristic	Patients	Controls	value
Median age (min–max)	39 (18-95)	40 (24-68)	0.97
Gender (male/female)	29/18	4/2
Median WBC (10 mL)	63	7.5	0.005
Median hemoglobin (gr/L)	8	13.5	0.0005
Plt (10)	30	274.5	0.0003
FAB classification		—	0.4
M0	6	—
M1	7	—
M2	10	—
M3	2	—
M4	16	—
M5	6	—
Patient karyotype
NK-AML	20	NA
Favorable	3	NA
Unfavorable	8	NA
Intermediate	1	NA
Unclassified	3	NA
Missed (unknown)	12	NA

Cytogenetic classification was based on WHO criteria. NK-AM: normal karyotype-AML. The meaning of a favorable response generally indicates an overall survival rate of about 50-60% for patients who achieve remission after therapy for AML with abnormalities involving chromosome 16,t(8;21), and perhaps even for the group that has deletion involving the long arm of chromosome 9. AML patients with unfavorable-risk cytogenetic abnormalities account for 16-30% of younger adult patients and have poor response to standard treatment, with only 32-55% achieving a complete response. The intermediate-risk cytogenetic subclass of AML includes cytogenetically normal (CN) and AML with other cytogenetic abnormalities and accounts for approximately 60% of all AML patients. NA: not available.